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ABSTRACT 
Objective: The objective of the study was to describe demographic, clinical features and drug treatment pattern among rheumatoid arthritis (RA) 
patients in a south Indian tertiary care hospital. 
Methods: In this retrospective study, a total of 789 patients diagnosed with RA were enrolled from October 2013 to December 2015 in tertiary care 
hospital irrespective of age and gender. Data of the patients were obtained from Medical Record Department (MRD), and all the data were 
documented in a suitable designed Case Record Form (CRF). The data were analyzed using SPSS 20.0 and Excel 2013. 
Results: There were 628 females and 161 males with mean age 47.6±12.6 and 47.1±14.4 y respectively. The ratio of male to female was 1:3.9. Most 
of the RA patients were housewives (66.4%). The mean disease duration was 4.3±4.5 y. The majority of patients (59.3%) had disease duration of 
more than 24 mo. Hypertension (21.5%) was the most common comorbid condition in our study population. Iron deficiency anemia (IDA) was 
observed in 10.6% of RA patients. Serum C-reactive protein (CRP) was positive in 89.3%. The majority of patients (87.7%) received DMARDs. As the 
disease, duration increased the severity of disease also increased. Majority of patients were prescribed with dual DMARDs in combination (52.3%). 
Conclusion: We observed female was dominant over the male in number and majority of patients had a later stage of the disease probably due to 
lack of medical facility or financial problems in the lower income groups. We observed that methotrexate plus hydroxychloroquine combination was 
commonly used in both high and moderate disease activity groups which may be due to a better outcome and minimal adverse effects. 
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INTRODUCTION 
Rheumatoid arthritis (RA) is a chronic autoimmune disease 
associated with polyarthritis and dysfunction of joints [1]. RA affects 
about 1% of the world population [2] and approximately 0.75% of 
the adult Indian population [3, 4]. RA exists all over the globe 
irrespective of different genders, age and socio-economic status [5]. 
However, the prevalence of RA increases with age and it is more 
pervasive in women than men in the ratio of 2:1 [6]. Various 
environmental risk factors such as smoking, alcohol, and vitamin D 
deficiency affects the development of RA [7]. Cigarette smoking 
elevates the level of the rheumatoid factor (RF) and anti-cyclic 
citrullinated peptide antibody (Anti-CCP) which are used as the 
clinical biomarker in the diagnosis of RA [8]. The occurrence and the 
severity of RA vary from different ethnic origin groups [4, 9, 10]. 
Comorbidities in RA are usually associated with poor progression 
and even reduce the life expectancy. Therefore, comorbidities are 
important in taking therapeutic decisions in RA patients [11-15]. 
Certain RA medications can induce comorbidities and studies have 
reported that these comorbidities can be appropriately managed in 
these patients [16-21]. The severity of the disease is represented by 
the disease activity score (DAS28) which uses 28 joint counts to 
monitor a patient’s disease severity of RA [22-27] and assess the 
patient’s response to treatment [28]. It is one of the recommended 
outcome measures in RA. The American College of Rheumatology 
(ACR) 2008 and 2012 also recommended the usage of DAS28 in 
therapy decision for RA due to its positive characteristics in 
reliability, validity, responsiveness and feasibility in clinical practice 
[29-31]. Disease-modifying antirheumatic drugs (DMARDs) are the 
mainstay in reducing the disease severity and progressive damage to 
joints [32, 33]. 
Presently there are no studies which explored the RA in detail 
regarding the demographics and drug treatment pattern in an Indian 
setting. The objective of the study was to understand the 
demography and drug treatment pattern in RA patients in a South 
Indian tertiary care teaching hospital. 
MATERIALS AND METHODS 
A retrospective observational study was conducted in a tertiary care 
teaching hospital of South India. The study was reviewed and 
approved by the Institutional Ethical Committee (IEC) (Registration 
Number ECR/146/Inst/KA/2013). A total number of 789 RA in 
patients’ medical records were collected from October 2013 to 
December 2015. The data of the patients were obtained from Medical 
Record Department (MRD). The study included patients of both 
genders diagnosed with RA according to the ACR classification criteria 
and at least admitted once in the hospital. The severity of disease was 
assessed by using DAS28 ESR and CRP scale. According to ACR, scales 
(0-9.4) were as follows: Remission: <2.6, Low: ≥2.6 to<3.2, Moderate: 
≥3.2 to ≤ 5.1, High: >5.1. However, patients who were shifted from 
treatment with modern medicines to other systems of treatment like 
Ayurveda or Unani were excluded from the study. All demographic 
details such as age, gender, laboratory parameters, comorbid 
conditions, clinical manifestations and the drug treatment pattern was 
obtained from medical records of patients. The data was analyzed 
using SPSS 20.0 and Excel 2013 as a statistical tool. All the categorical 
variables was expressed in proportion and analyzed by Chi-Square 
test. A continuous variable was expressed in terms of mean±SD and 
analysis was carried out by Independent T-test. 
RESULTS 
A total of 789 patients were admitted during the year 2013 to 2015 for 
the management of RA. The baseline demographic characteristic of 
patients is presented in table 1. The study population consisted of female 
patients 628 (79.6%) in the majority with male to female ratio of 1:3.9. 
The mean age of the study population was 47.5±13.0 y. For male 
patients, the mean age was 47.1±14.4 y and the mean age for female 
patients was 47.6±12.6 y. The mean of DAS28 ESR and DAS28 CRP was 
4.6±1.6 and 4.0±1.5 respectively. Based on the working status, the 
patients were categorized into different groups. Among the study 
population 524 (66.4%) were housewives followed by farmers 81 
(10.3%) and manual laborers 54 (6.9%). RA patients were categorized 
based on the body mass index (BMI). Among them 316 (40.1%) patients 
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were normal, 175 (22.2%) were obese and 75 (9.5%) were overweight. 
A total of 137 (17.4%) patients’ data on BMI was not available because 
patients’ body weight was not recorded. Mean disease duration for the 
study population was found to be 4.3±4.5 y. The majority of patients 468 
(59.3%) had a diagnosis of RA for more than 24 mo followed by 222 
(28.1%) patients had a diagnosis of RA between 6 to 24 mo and 99 
(12.5%) patients had disease duration of less than 6 mo. More than half 
428 (54.2%) of the RA patients belonged to the age group of 40-59. An 
age-wise distribution of patients with RA is depicted in fig. 1. 
Hypertension 170 (21.5%) and diabetes mellitus 140 (17.7%) were the 
most common comorbid conditions in RA patients. Hypothyroidism was 
observed in 56 (7.1%) followed by osteoarthritis 51 (6.5%) as shown in 
table 2. In the present study, we observed that iron deficiency anemia 
(IDA) was the most common in 84 (10.6%) patients. A total of 20 (2.5%) 
patients had anemia of chronic disease (ACD) and 19 (2.4%) patients 
had unclassified anemia. The distribution pattern of anemia in RA 
patients is shown in table 3. Patients exhibited prominent symptoms like 
multiple joint pain 601 (76.3%), morning stiffness 409 (51.9%), fevers 
156 (19.8%) and fatigue 124 (15.7%) as mentioned in table 4. 
Laboratory investigation in RA patients was given as in table 5. The 
mean erythrocyte sedimentation rate (ESR) of RA patients was found to 
be 59.1±28.0 mm/hr.  
 
Table 1: Baseline demographics characteristics of rheumatoid arthritis patients 
Characteristics No (%) n=789 mean±SD 
Sex   
 Female 628 (79.6)  
 Male 161 (20.4)  
Age   
 Female  47.6±12.6 
 Male  47.1±14.4 
Mean of DAS28    
 DAS28 ESR  4.6±1.6 
 DAS28 CRP  4.0±1.5 
Work Status   
 Housewife 524 (66.4)  
 Farmers 81 (10.3)  
 Labourers 54 (6.9)  
 Others 130 (16.5)  
Marital Status   
 Married 758 (96.1)  
 Single 31 (3.9)  
BMI   
 BMI not recorded (Unable to stand) 137 (17.4)  
 Below normal 86 (10.9)  
 Normal 316 (40.1)  
 Obese 175 (22.2)  
 Overweight 75 (9.5)  
Smoking   
 Non-Smoker 753 (95.4)  
 Ex-Smoker 14 (1.8)  
 Smoker 22 (2.8)  
Alcoholic   
 Non-alcoholic 771 (97.7)  
 Ex-alcoholic 3 (0.4)  
 Alcoholic 15 (1.9)  
Duration of disease (year)  4.3±4.5 
Disease duration (month)   
<6 99 (12.5)  
 6-24 222 (28.1)  
>24 468 (59.3)  
DAS: disease activity score, BMI: body max index  
 
Table 2: Comorbid conditions 
Comorbidities  No (%) n=789 Comorbidities  No (%) n=789 
Hypertension 170 (21.5) Respiratory infection 13 (1.7) 
Diabetes Mellitus 140 (17.7) Psychiatric disorder 12 (1.6) 
Hypothyroidism 56 (7.1) Tuberculosis 11 (1.4) 
Osteoarthritis 51 (6.5) Dyslipidemia 9 (1.1) 
Peptic ulcer  50 (6.3) Cataract surgery 9 (1.1) 
Asthma/COPD 42 (5.3) Connective tissue disease 9 (1.1) 
Cardio Vascular System Disorder 36 (4.6) Overlap syndrome 6 (0.8) 
Chikungunya 33 (4.2) Sjögren’s syndrome 6 (0.8) 
Urinary Tract Infection 33 (4.2) Ankylosis 4 (0.5) 
Gonarthrosis 26 (3.3) Osteonecrosis 4 (0.5) 
Vitamin D deficiency 18 (2.3) Glaucoma 3 (0.4) 
Interstitial pulmonary disease 17 (2.2) Stroke 2 (0.3) 
Osteoporosis 13 (1.6) Aortic arch syndrome Takayasu 2 (0.3) 
Systemic Lupus Erythematosus 12 (1.5) Raynaud’s syndrome 2 (0.3) 
Synovial hypertrophy 7 (0.9) Cellulitis of other parts of limb Axilla Hip Shoulder 2 (0.3) 
COPD: chronic obstructive pulmonary disease 
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The mean hemoglobin (Hb) of the study population was 110±18 g/l, 
followed by mean albumin (Alb) 37±15 g/l. Positive anti-CCP was 
observed in 75.7% of RA patients with a mean value of 133.3±70.9 
IU/ml. DAS28 ESR and DAS28 CRP were used to categorize the patients 
into high, moderate, low and remission disease activity score. By DAS28 
ESR, 256 (33%) patients had high disease activity whereas 399 (51.4%) 
patients had moderate activity. 
However, 121 (27.5%) patients had high disease activity and 171 
(38.9%) patients had moderate activity by DAS28 CRP. The total disease 
duration was compared with the severity of disease based on DAS28 
ESR and DAS28 CRP in RA patients as illustrated in fig. 2 and 3. It was 
observed that as the disease duration increased the disease severity 
index also increased significantly. A large number of patients were 
observed with moderate disease activity (28.5% DAS28 ESR and 19.8% 
DAS28 CRP) followed by high disease activity (19.8 % DAS28 ESR and 
15.9% DAS28 CRP) in the group which had a longer duration of illness 
(>24months). 
In our study, we observed that 693 (87.7%) patients were 
prescribed with DMARDs followed by NSAIDs 510 (64.4%) as 
mentioned in table 6. Among the DMARDs, the majority of patients 
received dual therapy 413 (52.3%) followed by monotherapy 206 
(26.0%). Among dual therapy methotrexate plus hydroxyl-
chloroquine 279 (35.4%) was prescribed in highest number as 
shown in table 7. Different combinations of DMARDs were 
categorized based on disease severity and duration of illness in table 
8. It was observed that methotrexate plus hydroxychloroquine 
(MTX+HCQ) combination was prescribed the most in high, moderate 
and low disease activity in all the RA patients. 
 
Table 3: Frequency of anemia among the rheumatoid arthritis patients 
Types of anemia No (%) n=789 
IDA 84 (10.6) 
ACD 20 (2.5) 
Unclassified anemia 19 (2.4) 
Dual anemia 6 (0.7) 
Vitamin B12 deficiency 4 (0.5) 
Autoimmune hemolytic anemia 1 (0.1) 
Aplastic anemia 1 (0.1) 
 IDA: iron deficiency anemia, ACD: anemia of chronic disease  
 
Table 4: Prominent symptoms among rheumatoid arthritis patients 
Symptoms No (%) n=789 
Multiple joint pain 601 (76.3) 
Morning stiffness 409 (51.9) 
Fever 156 (19.8) 
Fatigue 124 (15.7) 
 
Table 5: Distribution of lab values and serological biomarkers in rheumatoid arthritis patients 
Lab parameters mean±SD Positive (%) 
ESR  59.1±28.0 mm/hr  
RF 111.5±48.6 IU/ml 68.4 
Anti-CCP 133.3±70.9 IU/ml 75.7 
CRP 37.1±46.4 mg/l 89.3 
Hb 110±18 g/l  
Alb 37±15 g/l  
Iron 6.2±3.6 µmol/l  
TIBC 50.5±15.4 µmol/l  
Ferritin 3.2±5.5 pmol/l  
ESR: erythrocyte sedimentation rate, RF: rheumatoid factor, Anti-CCP: anti-cyclic citrullinated peptide, CRP: C-reactive protein, Hb: hemoglobin, Alb: 
albumin, TIBC: total iron binding capacity  
 
Table 6: Treatment pattern in rheumatoid arthritis patients 
Treatment No (%) n=789 
DMARDs 693 (87.7) 
Corticosteroid (prednisolone) 321 (40.7) 
NSAIDs 510 (64.4) 
2 DMARDs+1 NSAIDs 162 (20.5) 
2 DMARDs+1 NSAIDs+1 Steroid 42 (5.3) 
2 DMARDs+2 NSAIDs 61 (7.7) 
2 DMARDs+1 Steroid 77 (9.8) 
Biological DMARDs  1 (0.1) 
Multivitamin 214 (27.1) 
Calcium with Vitamin 257 (32.6) 
Glucosamine supplement 47 (6.0) 
DMARDs: disease-modifying antirheumatic drugs, NSAIDs: nonsteroidal anti-inflammatory drugs 
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Table 7: Treatment pattern of non-biological DMARDs combination 
DMARDs combination No. (%) Non-biological DMARDs No (%) n=789 
Monotherapy  
206 (26.0%) 
SSZ 34 (4.3) 
MTX 84 (10.6) 
LEF 5 (0.6) 
HCQ 80 (10.1) 
AZA 3 (0.4) 
Dual drug combination 
413 (52.3%) 
MTX+SSZ 50 (6.3) 
MTX+HCQ 279 (35.4) 
MTX+LEF 5 (0.6) 
SSZ+HCQ 69 (8.7) 
HCQ+LEF 5 (0.6) 
SSZ+LEF 2 (0.3) 
HCQ+AZA 3 (0.4) 
Triple drug combination 
73 (9.2%) 
MTX+LEF+HCQ 5 (0.6) 
MTX+SSZ+HCQ 67 (8.5) 
SSZ+MTX+LEF 1 (0.1) 
Four drug combination 
1 (0.1%) 
MTX+SSZ+HCQ+LEF 1 (0.1) 
No DMARDs  96 (12.2) 
SSZ: sulphasalazine, MTX: methotrexate, HCQ: hydroxychloroquine, LEF: leflunomide, AZA: azathioprine  
 
Table 8: DMARDs vs. DAS28 ESR and duration of disease 
 DAS28 ESR  
DMARDS Disease activity score High Moderate Low Remission 
Duration of disease <6 6-24 >24 <6 6-24 >24 <6 6-24 >24 <6 6-24 >24 
No DMARDs 1 4 7 7 15 31 1 2 9 1 4 10 
SSZ 0 2 7 3 6 7 2 2 3 2 0 0 
MTX 2 11 18 2 14 29 0 0 2 0 2 1 
HCQ 3 7 8 6 13 23 1 3 10 0 1 4 
MTX+SSZ 0 4 18 3 6 12 0 1 2 0 1 3 
MTX+HCQ 15 34 66 17 39 70 0 5 16 0 3 9 
MTX+LEF 0 0 1 0 0 3 0 0 1 0 0 0 
SSZ+HCQ 2 7 10 11 9 22 1 1 1 1 2 2 
MTX+SSZ+HCQ 1 7 14 12 13 14 3 0 2 0 0 1 
DMARDs: disease-modifying antirheumatic drugs, SSZ: sulphasalazine, MTX: methotrexate, HCQ: hydroxychloroquine, LEF: leflunomide, AZA: 
azathioprine, MIN: minocycline  
 
 
Fig. 1: Age-wise distribution of rheumatoid arthritis patients 
 
 
Fig. 2: DAS28 ESR vs. duration of disease 
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Fig. 3: DAS28 CRP vs. duration of disease 
 
DISCUSSION 
RA is the chronic autoimmune disease in developing countries like 
India, especially associated with disease-related complication, 
physical disability, and early mortality because of lack of awareness 
of patients regarding the disease or maybe noncompliance to the 
therapy which could be due to the high cost of management or 
temporary improvement of illness. Therefore, it is important to 
understand the magnitude of the problem of the disease especially 
in countries like India. The study analyzed demographic, clinical, 
comorbid, serological and treatment data on the patients with RA in 
the South region of India. This study revealed that prevalence of RA 
was more in female patients than male patients (79.6% vs. 20.4% 
respectively) which were almost similar to studies conducted by Al-
Bishri et al. (78% vs. 22% respectively) [15] and Bajraktari et al. 
(76.8% vs. 23.2% respectively) [34]. In this research, we observed 
that male to female ratio was 1: 3.9 which was very close to 1: 4 
ratio observed by Aletaha et al. [35] study and 1: 3.5 ratio reported 
by Al-Bishri et al. [15]. Whereas in a study conducted by Owino et al. 
[36] male to female ratio (1: 6.5) was higher than the ratio in this 
study. This higher ratio can be attributed to hormonal differences 
between female and male patients [37]. Our study showed that the 
peak prevalence of RA was in the age group of 40-49 followed by 50-
59 in both the genders. In our study, the female was dominant over 
the male in number in all the age groups. A similar result was 
observed in Bajraktari et al. [34] study with respect to peak 
prevalence of RA distribution. But a study by Owino et al. [36] 
showed that the peak prevalence of RA was higher, especially in the 
younger age groups of 20-29 and 40-49. In our study, the vast 
majority of registered RA patients were housewives (66.4%) 
whereas, a study by Bajraktari et al. [34] showed the majority of 
patients were farmers followed by housewives (38% and 32.2% 
respectively). The higher prevalence of RA among the housewives or 
farmers was probably due to prolonged the duration of physical 
work with standing posture in the household work or agricultural 
field. We did not observe a correlation between RA prevalence and 
higher BMI although, it was reported that higher BMI has negative 
effects on the treatment of RA, Gremese et al. and Ajeganova et al. 
[38,39] emphasizing the need for weight control during the course 
of treatment. In this study, we observed much lower rates of 
smoking (2.8%) and almost similar alcohol consumption (1.9%) 
compared to the study by Bal et al. (16.2% and 2.0% respectively) 
[40]. This could be due to the uncommon practice of smoking and 
alcohol consumption especially in the female population in India. 
According to literature, smoking is known to be a risk factor for the 
development of RA [41, 42]. Also, smoking interferes with the course 
of treatment causing the poor outcome. Hence, this indicates the 
need for awareness among RA patients on the negative effect of 
smoking. Among most common symptoms of RA in our study 
multiple joint pain (76.3%) followed by morning stiffness (51.9%), 
fever (19.8%) and fatigue (15.7%) was observed considerably. It 
was found in our study that hypertension (21.5%) was the most 
common comorbidity followed by diabetes mellitus (17.7%) which 
was similar to the study conducted by Al-Bishri et al. [15]. There is 
also a report of peptic ulcer and diabetes as major comorbidity after 
hypertension in the East African study by Owino et al. [36] and Bal et 
al. [40]. ACD and IDA are the most common type of anemia in RA 
patients [43, 44]. IDA (10.6%) was the most prevalent anemia 
among our RA patients followed by ACD (2.5%). IDA may be caused 
due to prednisolone or NSAIDs leading to chronic blood loss by 
gastritis, peptic ulcer and gastroesophageal reflux [45]. In this study, 
serum RF was positive in 68.4% (mean 111.5±48.6 IU/ml), anti-CCP 
was positive in 75.7% (mean 133.3±70.9 u/ml) and CRP was 
positive in 89.3% (mean 37.1±46.4 mg/l). Positive serum RF was 
found to be similar to study by Bal et al. (69.2%) [40] but lower than 
the study by Owino et al. and Inoue et al. (78.9% and 77.3% 
respectively) [36, 46]. The mean value of DAS28 ESR (4.6±1.6) was 
higher than the mean value of DAS28 CRP (4.0±1.5). We observed 
that as the disease duration increased the severity of the disease 
activity scores also increased. Patients with longer duration disease 
(>24 mo and 6-24 mo) had the highest number of disease severity 
index belonged to either moderate or high disease activity. In our 
study, we observed that non-biological DMARDs (87.7%) was 
prescribed most commonly followed by NSAIDs (64.4%). Among the 
non-biological DMARDs, hydroxychloroquine (63.5%) prescribed 
more commonly followed by methotrexate (62.4%) and 
sulphasalazine (28.1%). Only one patient received biological 
DMARDs (etanercept) (0.1%) during the study period. Whereas in a 
study by Bal et al. [40] hydroxychloroquine was prescribed only to 
15.8% of RA patients. However, we could not find any prescription 
of cyclosporine, gold, thiomalate and D-penicillamine drugs in our 
hospital record most of which are associated with higher incidence 
of adverse drug reactions (ADRs) and availability of safer drugs with 
better efficacy for the treatment of RA patients. In a study by Al-
Bishri et al. [15], prednisolone (80.8%) was prescribed the most 
commonly followed by methotrexate (74.4%).  
Moreover, 7.6% patients received biological DMARDs (etanercept). 
A study by Almeida et al. [47] showed that the treatment of RA 
patients most frequently included methotrexate (39.8%) followed 
by antimalarial (30.6%) and prednisolone (30.6%) with anti-TNF 
alpha (3.06%) least in number. It indicates that the non-biological 
DMARDs drugs are frequently prescribed compared to biological 
DMARDs [48-50]. In our study, most patients received dual DMARDs 
(52.3%) in combination followed by monotherapy DMARDs 
(26.0%). DAS28 ESR score was calculated to obtain the severity of 
the disease and compared with the duration of disease along with 
DMARDs combinations. It was observed that the majority of patients 
were prescribed with the DMARDs in the late stage of the disease. 
Among the DMARDs combinations, Methotrexate plus Hydroxy-
chloroquine (35.4%) was prescribed to the majority of the patients 
with all stages of severity. However, the number of patients who 
received methotrexate plus hydroxychloroquine increased as the 
disease duration and severity of disease activity increased. 
CONCLUSION  
This study mainly focused on the demographical details, clinical 
characteristics and treatment pattern in RA patients in South India. 
We observed female was dominant over the male in number and the 
majority of the patients had the later stage of the disease probably 
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due to lack of medical facility or financial problems in the lower 
income groups. The end stage of the disease was always associated 
with poor prognosis with multiple drug therapy. In our study, we 
observed methotrexate plus hydroxychloroquine were the major 
combinations which was most effectively used in both high and 
moderate disease severity groups probably due to a better outcome 
and least side effects. The use of steroids was limited compared to 
non-biological DMARDs and there were used if there was any 
relapse or poor prognosis. 
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